Anne O’Hagan

2.5k total citations
23 papers, 776 citations indexed

About

Anne O’Hagan is a scholar working on Molecular Biology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anne O’Hagan has authored 23 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 16 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anne O’Hagan's work include Fibroblast Growth Factor Research (16 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Urinary and Genital Oncology Studies (6 papers). Anne O’Hagan is often cited by papers focused on Fibroblast Growth Factor Research (16 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Urinary and Genital Oncology Studies (6 papers). Anne O’Hagan collaborates with scholars based in United States, France and Spain. Anne O’Hagan's co-authors include Vicki Goodman, Richard Kefford, Dirk Schadendorf, Georgina V. Long, Jolly Mazumdar, Patricia Haney, Ravi K. Amaravadi, Mary Guckert, Tabea Wilhelm and Paolo A. Ascierto and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Anne O’Hagan

23 papers receiving 764 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne O’Hagan United States 11 483 423 220 183 143 23 776
Monica Kong-Beltran United States 10 471 1.0× 219 0.5× 149 0.7× 302 1.7× 241 1.7× 11 918
Matthew Dankner Canada 12 390 0.8× 374 0.9× 119 0.5× 51 0.3× 222 1.6× 29 747
Sujatha Nallapareddy United States 10 509 1.1× 440 1.0× 122 0.6× 39 0.2× 141 1.0× 16 790
Yuchen Bai United States 14 693 1.4× 452 1.1× 226 1.0× 66 0.4× 218 1.5× 21 1.0k
Andrea Milani Italy 12 268 0.6× 416 1.0× 123 0.6× 67 0.4× 208 1.5× 35 765
Jerry Haney United States 7 846 1.8× 482 1.1× 362 1.6× 44 0.2× 296 2.1× 12 1.2k
Nyam Kamsu-Kom France 10 662 1.4× 615 1.5× 80 0.4× 32 0.2× 117 0.8× 12 1.0k
Anne Marie Mazzola United States 7 388 0.8× 224 0.5× 145 0.7× 70 0.4× 147 1.0× 11 664
Sumie Koike Japan 13 520 1.1× 669 1.6× 199 0.9× 66 0.4× 506 3.5× 19 1.0k
Young‐Kwang Yoon South Korea 13 412 0.9× 442 1.0× 104 0.5× 45 0.2× 203 1.4× 22 736

Countries citing papers authored by Anne O’Hagan

Since Specialization
Citations

This map shows the geographic impact of Anne O’Hagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne O’Hagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne O’Hagan more than expected).

Fields of papers citing papers by Anne O’Hagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne O’Hagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne O’Hagan. The network helps show where Anne O’Hagan may publish in the future.

Co-authorship network of co-authors of Anne O’Hagan

This figure shows the co-authorship network connecting the top 25 collaborators of Anne O’Hagan. A scholar is included among the top collaborators of Anne O’Hagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne O’Hagan. Anne O’Hagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loriot, Yohann, Anne O’Hagan, & Arlene O. Siefker‐Radtke. (2023). Plain Language Summary of Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma: A Phase 2 Study with Long-Term Follow-up. Future Oncology. 20(5). 231–243. 4 indexed citations
2.
Siefker‐Radtke, Arlene O., Andrea Necchi, Se Hoon Park, et al.. (2023). Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. European Urology Open Science. 50. 1–9. 10 indexed citations
3.
Siefker‐Radtke, Arlene O., Thomas Powles, Víctor Moreno, et al.. (2023). Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.. Journal of Clinical Oncology. 41(16_suppl). 4504–4504. 24 indexed citations
4.
Dosne, Anne‐Gaëlle, Elodie Valade, Nele Goeyvaerts, et al.. (2022). Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer Chemotherapy and Pharmacology. 89(2). 151–164. 7 indexed citations
5.
Dosne, Anne‐Gaëlle, Elodie Valade, Kim Stuyckens, et al.. (2021). Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer. CPT Pharmacometrics & Systems Pharmacology. 11(5). 569–580. 10 indexed citations
6.
7.
Siefker‐Radtke, Arlene O., Andrea Necchi, Se Hoon Park, et al.. (2021). Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 39(6_suppl). 426–426. 1 indexed citations
8.
9.
10.
Moreno, Víctor, Yohann Loriot, Piotr Rutkowski, et al.. (2020). Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. Journal of Clinical Oncology. 38(15_suppl). 3055–3055. 1 indexed citations
11.
Santiago-Walker, Ademi, Christopher Moy, Yohann Loriot, et al.. (2019). Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC).. Journal of Clinical Oncology. 37(7_suppl). 420–420. 3 indexed citations
12.
13.
Siefker‐Radtke, Arlene O., Andrea Necchi, Se Hoon Park, et al.. (2018). First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. Journal of Clinical Oncology. 36(15_suppl). 4503–4503. 54 indexed citations
14.
15.
Siefker‐Radtke, Arlene O., Begoña Mellado, Karel Decaestecker, et al.. (2016). A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations.. Journal of Clinical Oncology. 34(15_suppl). TPS4575–TPS4575. 6 indexed citations
16.
Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations
17.
Ouellet, Danièle, Ekaterina Gibiansky, Anne O’Hagan, et al.. (2014). Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. The Journal of Clinical Pharmacology. 54(6). 696–706. 57 indexed citations
18.
Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2014). Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).. Journal of Clinical Oncology. 32(15_suppl). 9034–9034. 6 indexed citations
19.
Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations
20.
O’Hagan, Anne, et al.. (2004). Miliary Neonatal Hemangiomatosis with Fulminant Heart Failure and Cardiac Septal Hypertrophy in Two Infants. Pediatric Dermatology. 21(4). 469–472. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monica Kong-Beltran Breakdown of academic impact, for papers by Matthew Dankner Breakdown of academic impact, for papers by Sujatha Nallapareddy Breakdown of academic impact, for papers by Yuchen Bai Breakdown of academic impact, for papers by Andrea Milani Breakdown of academic impact, for papers by Jerry Haney Breakdown of academic impact, for papers by Nyam Kamsu-Kom Breakdown of academic impact, for papers by Anne Marie Mazzola Breakdown of academic impact, for papers by Sumie Koike Breakdown of academic impact, for papers by Young‐Kwang Yoon
Rankless by CCL
2026